Drug Profile
HX 100
Alternative Names: HX-100; TRPA1 Antagonist - Eli Lilly and CompanyLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Hydra Biosciences
- Class Antiallergics; Antiasthmatics; Small molecules
- Mechanism of Action TRPA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic asthma; Neuropathic pain
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Canada (PO)
- 14 Nov 2019 Phase I development in Neuropathic pain is ongoing in Canada (PO) (Eli Lilly pipeline, November 2019)
- 14 Dec 2018 Eli Lilly acquires TRPA1 antagonists programme from Hydra Biosciences